Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapy
Clinical trial data presented at IDWeek 2026 shows that the investigational drug asuptegravir significantly reduces HIV-1 RNA levels in treatment-naive patients. The study demonstrated a clear dose-response relationship and effective viral suppression when combined with other therapies.
Why it matters
The development of new integrase inhibitors is critical for improving treatment options and viral suppression rates for people living with HIV.
Asuptegravir (Jiangsu Aidea Pharmaceutical), an investigational integrase strand transfer inhibitor, reduced HIV-1 RNA by 1.49 to 2.36 log10 copies/mL after 10 days of monotherapy in treatment-naive people with HIV, with a clear dose-response relationship.1 Hong Qin, MD, PhD, chief medical officer of Aidea, presented phase 1 and phase 1/2 data at IDWeek 2026, held October 21-24 in Washington, DC.1,2 A third poster reported final 48-week results from the RECOVER study of fostemsavir in immunologic nonresponders.3
Asuptegravir is metabolized by UGT1A1 and is being evaluated alongside emtricitabine and tenofovir alafenamide (FTC/TAF).2 Immunologic nonresponders, defined as people with CD4+ T-cell counts persistently below 350 cells/mm3 despite at least 2 years of viral suppression, face higher risks of AIDS progression, non-AIDS events, and death.3
Asuptegravir Antiviral Activity and Pharmacokinetics in Phase 1 and 1/2 Trials
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in